India Globalization Capital Inc. (IGC)

0.77
0.05 5.79
AMEX : Health Technology
Prev Close 0.82
Open 0.85
Day Low/High 0.75 / 0.86
52 Wk Low/High 0.25 / 1.63
Volume 378.25K
Avg Volume 1.36M
Exchange AMEX
Shares Outstanding 28.09M
Market Cap 21.06M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

IGC Announces Adjournment Of Annual Meeting Voting For Proposals Three And Four To Dec 29, 2017

IGC Announces Adjournment Of Annual Meeting Voting For Proposals Three And Four To Dec 29, 2017

Seeks to Obtain a Quorum of Voting Stockholders Owning Shares as of October 5, 2017

IGC Announces Adjournment Of Annual Meeting Voting For Proposals Three And Four To Dec 15, 2017

IGC Announces Adjournment Of Annual Meeting Voting For Proposals Three And Four To Dec 15, 2017

Seeks to Obtain a Quorum of Voting Stockholders Owning Shares as of October 5, 2017 

IGC-AD1 Targeting Alzheimer's Disease To Be Commercialized In Early 2018 Through Medical Dispensaries

IGC-AD1 Targeting Alzheimer's Disease To Be Commercialized In Early 2018 Through Medical Dispensaries

IGC-AD1 for Alzheimer's Shows Promise by Inhibiting GSK3ß and Tau hyperphosphorylation a key hallmark of AD

IGC Prepares A Liquid Delivery Formulation Of IGC-AD1 For Alzheimer's Based On Novel In Vitro Data

IGC Prepares A Liquid Delivery Formulation Of IGC-AD1 For Alzheimer's Based On Novel In Vitro Data

Readies Line of Medical Dispensary Products Targeting Enhanced Mitochondrial Function in AD patients

IGC Readies Line Of Medical Dispensary Products Targeting Alzheimer's Disease Based On Novel Data

IGC Readies Line Of Medical Dispensary Products Targeting Alzheimer's Disease Based On Novel Data

Drug Candidate for Alzheimer's Shows Promise by Inhibiting Aß Aggregation without Neuron Damage

IGC Announces Financial Results For Quarter Ended June 30, 2017

IGC Announces Financial Results For Quarter Ended June 30, 2017

Alzheimer's Licensing Agreement Highlights Cannabis-Based IP Portfolio Targeting Large Market Conditions

IGC Announces Financial Results For Fiscal Year Ended March 31, 2017

IGC Announces Financial Results For Fiscal Year Ended March 31, 2017

Core Operations Transitioned to Phytocannabinoid-Based Therapy Development Targeting Large Market Indications

IGC Sells Malaysian Hotel Investment Interest

Consolidates Corporate Focus to the Development of Cannabis-Based Combination Therapies

IGC Announces Third Quarter Financial Results

Transitions Management to Focus on Cannabis-based Therapies

IGC Update On Iron Ore Subsidiary

IGC Update On Iron Ore Subsidiary

TheStreet Quant Rating: D (Sell)